1-3 of 3
Kris Vaddi, PhD, DVM
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,

Paola Guglielmelli, MD, PhD, Lisa Pieri, MD, Enrico Tagliarico, MD, Roberta Zini, BiSci, Ruggiero Norfo, PhD, Alberto Bosi, Kris Vaddi, PhD, DVM, Timothy Burn, PhD, Nancy Contel, Srdan Verstovsek, MD, PhD, Rossella Manfredini, BiSci, PhD, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2011) 118 (21): 3852.
https://doi.org/10.1182/blood.V118.21.3852.3852
Published: 2011
Journal Articles

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).

Srdan Verstovsek, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Deborah Thomas, MD, Jorge Cortes, MD, Ruben A. Mesa, MD, FACP, William J. Hogan, MBChB, John R. Redman, MD, Sue Erickson-Viitanen, Richard Levy, MD, Kris Vaddi, PhD, DVM, Edward Bradley, MD, Jordan Fridman, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 1762.
https://doi.org/10.1182/blood.V112.11.1762.1762
Published: 2008
Journal Articles

Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424

Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Timothy Burn, PhD, Kris Vaddi, PhD, DVM, John Redman, MD, Edward C Bradley, MD, Richard Levy, MD, Steven Friedman, MD, Gregory Hollis, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 2802.
https://doi.org/10.1182/blood.V112.11.2802.2802
Published: 2008